DRD3

Summary

DRD3 (dopamine receptor D3, HGNC:3024) is a protein-coding gene on chromosome 3q13.31, encoding D(3) dopamine receptor (P35462). Dopamine receptor that is primarily expressed in limbic areas of the brain and is involved in the modulation of cognitive, emotional, and endocrine functions.

This gene encodes the D3 subtype of the five (D1-D5) dopamine receptors. The activity of the D3 subtype receptor is mediated by G proteins which inhibit adenylyl cyclase. This receptor is localized to the limbic areas of the brain, which are associated with cognitive, emotional, and endocrine functions. Genetic variation in this gene may be associated with susceptibility to hereditary essential tremor 1. Alternative splicing of this gene results in transcript variants encoding different isoforms, although some variants may be subject to nonsense-mediated decay (NMD).

Source: NCBI Gene 1814 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 73 total
• GTEx eGene: eQTL in 1 tissue, sQTL in 1 (q < 0.05)
• Phenotypes (HPO): 12
• Drug target: yes — 11 curated mechanism-of-action drugs, 21 via a complex or family; 448 molecules with ChEMBL bioactivity (top 1% of genes corpus-wide)
• Approved drugs (ChEMBL mechanism of action): 4 — Blonanserin, Cariprazine Hydrochloride, Chlorprothixene, +1 more
• Approved drugs acting on a complex or family including it: 20 — Amisulpride, Amoxapine, Apomorphine Hydrochloride, +17 more (Dopamine receptors; D2 & D3; Dopamine receptor)
• Constraint (gnomAD): pLI 0.66 (intermediate), LOEUF 0.60 (unconstrained)
• MANE Select transcript: NM_000796
• Notable: 73 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3024
Approved symbol	DRD3
Name	dopamine receptor D3
Location	3q13.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151577
Ensembl biotype	protein_coding
OMIM	126451
Entrez	1814

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 nonsense_mediated_decay

MANE Select: ENST00000383673

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 1, TSL 5: 1

ENST00000383673, ENST00000295881, ENST00000460779, ENST00000467632, ENST00000698213

RefSeq mRNA: 4 — MANE Select: NM_000796 NM_000796, NM_001282563, NM_001290809, NM_033663

CCDS: CCDS2978, CCDS33829

Canonical transcript exons

ENST00000383673 — 7 exons

Exon	Start	End
ENSE00001000454	114159755	114159867
ENSE00001157158	114147415	114147557
ENSE00001194749	114139500	114139696
ENSE00001225059	114171723	114172027
ENSE00001384028	114178657	114179052
ENSE00003972975	114127580	114128912
ENSE00003972976	114131118	114131400

Expression profiles

Bgee: expression breadth broad, 25 present calls, max score 92.21.

Highest expression (Bgee): male germ line stem cell (sensu Vertebrata) in testis, metanephric glomerulus, endometrium epithelium, nucleus accumbens, putamen.

Genetic regulation across tissues (GTEx eQTL / sQTL)

DRD3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 1 tissue and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

2 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	eqtl	3.6e-30	+0.80	3:114212674:G:T
Testis	sqtl	4.6e-02	-0.64	3:114224783:C:G

Top tissues by expression

showing 100 of 245 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.21	gold quality
metanephric glomerulus	UBERON:0004736	72.03	gold quality
endometrium epithelium	UBERON:0004811	71.54	gold quality
nucleus accumbens	UBERON:0001882	68.32	gold quality
putamen	UBERON:0001874	57.71	gold quality
caudate nucleus	UBERON:0001873	56.22	gold quality
granulocyte	CL:0000094	55.00	gold quality
thymus	UBERON:0002370	51.82	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.85	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
paraflocculus	UBERON:0005351	50.18	gold quality
lower lobe of lung	UBERON:0008949	49.59	silver quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
layer of synovial tissue	UBERON:0007616	46.56	gold quality
quadriceps femoris	UBERON:0001377	46.10	gold quality
vastus lateralis	UBERON:0001379	45.23	gold quality
trachea	UBERON:0003126	44.40	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
oviduct epithelium	UBERON:0004804	42.62	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
dorsal root ganglion	UBERON:0000044	41.10	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality
amniotic fluid	UBERON:0000173	40.69	gold quality
dorsal plus ventral thalamus	UBERON:0001897	40.64	gold quality
jejunal mucosa	UBERON:0000399	40.59	gold quality
biceps brachii	UBERON:0001507	40.57	gold quality
epithelium of nasopharynx	UBERON:0001951	40.45	gold quality
myocardium	UBERON:0002349	40.45	gold quality
gingival epithelium	UBERON:0001949	40.43	gold quality
germinal epithelium of ovary	UBERON:0001304	40.33	gold quality
esophagus squamous epithelium	UBERON:0006920	40.29	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	40.27	gold quality
jejunum	UBERON:0002115	40.18	gold quality
prefrontal cortex	UBERON:0000451	40.07	silver quality
cartilage tissue	UBERON:0002418	40.06	gold quality
epithelium of bronchus	UBERON:0002031	40.02	gold quality
superior frontal gyrus	UBERON:0002661	40.00	gold quality
bronchus	UBERON:0002185	39.99	gold quality
mammary duct	UBERON:0001765	39.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	39.95	gold quality
primary visual cortex	UBERON:0002436	39.87	gold quality
colonic mucosa	UBERON:0000317	39.85	gold quality
deltoid	UBERON:0001476	39.83	gold quality
occipital lobe	UBERON:0002021	39.83	gold quality
saphenous vein	UBERON:0007318	39.83	gold quality
parotid gland	UBERON:0001831	39.81	gold quality
oocyte	CL:0000023	39.80	gold quality
urethra	UBERON:0000057	39.80	gold quality
heart right ventricle	UBERON:0002080	39.79	gold quality
pericardium	UBERON:0002407	39.77	gold quality
endothelial cell	CL:0000115	39.75	gold quality
synovial joint	UBERON:0002217	39.70	gold quality
nipple	UBERON:0002030	39.68	gold quality
bronchial epithelial cell	CL:0002328	39.65	gold quality
decidua	UBERON:0002450	39.65	gold quality
penis	UBERON:0000989	39.64	gold quality
gingiva	UBERON:0001828	39.64	gold quality
trigeminal ganglion	UBERON:0001675	39.63	gold quality
tendon of biceps brachii	UBERON:0008188	39.60	gold quality
inferior vagus X ganglion	UBERON:0005363	39.57	gold quality
superior surface of tongue	UBERON:0007371	39.56	gold quality
pylorus	UBERON:0001166	39.55	gold quality
forebrain	UBERON:0001890	39.55	gold quality
renal medulla	UBERON:0000362	39.53	gold quality
pons	UBERON:0000988	39.51	gold quality
medulla oblongata	UBERON:0001896	39.48	gold quality
superior vestibular nucleus	UBERON:0007227	39.47	gold quality
cardia of stomach	UBERON:0001162	39.46	gold quality
parietal pleura	UBERON:0002400	39.45	gold quality
Brodmann (1909) area 23	UBERON:0013554	39.40	gold quality
tongue	UBERON:0001723	39.37	gold quality
oral cavity	UBERON:0000167	39.35	gold quality
subthalamic nucleus	UBERON:0001906	39.35	gold quality
ventral tegmental area	UBERON:0002691	39.35	gold quality
parietal lobe	UBERON:0001872	39.32	gold quality
vena cava	UBERON:0004087	39.31	gold quality
pharyngeal mucosa	UBERON:0000355	39.27	gold quality
substantia nigra pars compacta	UBERON:0001965	39.23	gold quality
visceral pleura	UBERON:0002401	39.23	gold quality
postcentral gyrus	UBERON:0002581	39.23	gold quality
body of tongue	UBERON:0011876	39.22	gold quality
medial globus pallidus	UBERON:0002477	39.18	gold quality
trabecular bone tissue	UBERON:0002483	39.18	gold quality
globus pallidus	UBERON:0001875	39.15	gold quality
substantia nigra pars reticulata	UBERON:0001966	39.11	gold quality
entorhinal cortex	UBERON:0002728	39.05	gold quality
nasal cavity epithelium	UBERON:0005384	39.04	gold quality
lateral nuclear group of thalamus	UBERON:0002736	39.00	gold quality
corpus epididymis	UBERON:0004359	38.98	gold quality
ganglionic eminence	UBERON:0004023	38.96	gold quality
tibia	UBERON:0000979	38.93	gold quality
lateral globus pallidus	UBERON:0002476	38.81	gold quality
seminal vesicle	UBERON:0000998	38.75	gold quality
caput epididymis	UBERON:0004358	38.75	gold quality
cauda epididymis	UBERON:0004360	38.74	gold quality
middle temporal gyrus	UBERON:0002771	38.72	gold quality
mammalian vulva	UBERON:0000997	38.66	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.10

HPA expression

RNA tissue specificity: Tissue enriched

37 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Basal ganglia	tissue	26.2
Putamen	tissue	18.3
Ventral forebrain	tissue	17.7
Septum	tissue	12.3
Nucleus accumbens	tissue	9.6
Midbrain	tissue	2.8
Olfactory bulb	tissue	2.6
Thalamus	tissue	2.5
Cerebellum	tissue	2.5
Pons	tissue	2.3
Amygdala	tissue	2.3
Cerebral cortex	tissue	2.2
Temporal cortex	tissue	2.2
Medulla oblongata	tissue	2.1
Insular cortex	tissue	2.1
Retrosplenial and cingulate cortex	tissue	2.0
Retrosplenial cortex	tissue	1.9
Hippocampal formation	tissue	1.8
Prefrontal cortex	tissue	1.7
Motor cortex	tissue	1.7
Hypothalamus	tissue	1.7
Superior colliculi	tissue	1.7
Entorhinal cortex	tissue	1.7
Periaqueductal gray	tissue	1.7
Occipital cortex	tissue	1.7
Substantia nigra	tissue	1.6
Caudate putamen	tissue	1.6
Spinal cord	tissue	1.5
Somatosensory cortex	tissue	1.5
Corpus callosum	tissue	1.4
Hippocampus	tissue	0.7
Testis	tissue	0.6
Locus coeruleus	tissue	0.6
Postcentral gyrus	tissue	0.6
Choroid plexus	tissue	0.4
Retina	tissue	0.1
Frontal cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Mammillary body (7.8), Caudate nucleus (4.0), Nucleus basalis of Meynert (2.5), Piriform cortex (2.2), Nucleus of the diagonal band (1.9).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1D1, RORA

Functional genomics

gnomAD constraint: pLI 0.658, LOEUF 0.604, missense Z 1.09 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000383673 — one region, missense o/e 0.92.

Literature-anchored findings (GeneRIF, showing 40)

• Significant association of schizophrenia with DRD3 haplotype pairs, which includes 4 SNPs in a 768 bp region with the S9G polymorphism. (PMID:10670776)
• The Ser9Gly polymorphism in the DRD3 gene are not associated with EH. However, our negative result does not exclude the possibility of another variant elsewhere in or near the DRD3 gene in EH (PMID:11796958)
• it is unlikely that DRD3 is playing a major role in the etiology of attention-deficit hyperactivity disorder (PMID:11864723)
• ABP-280 interacts with dopamine D(3) receptors. (PMID:11911837)
• characterisation, mutation detection, and association analysis of alternative promoters and 5’ UTRs of the human gene in schizophrenia (PMID:12082567)
• Gly/Gly homozygotes in MscI polymorphic site of dopamine d3 receptor gene may be involved in pathogenesis of tardive dyskinesia in schizophrenics (PMID:12109967)
• protein 4.1N/dopamine receptor interaction is required for localization or stability of dopamine receptors at the neuronal plasma membrane. (PMID:12181426)
• An epistatic interaction of the PDYN gene polymorphism with the GLY allele of the DRD3 gene may contribute to susceptibility for schizophrenia. (PMID:12207142)
• This study suggests that these polymorphisms are not related to the development of tardive dystonia. (PMID:12210290)
• no association between this gene and Korean alcohol dependence (PMID:12218663)
• Significant age-related decline was observed for dopamine receptor mRNAs in the hippocampus and entorhinal cortex (PMID:12509874)
• DRD3 polymorphisms investigated have no major impact on personality in the investigated population (PMID:12555237)
• Meta-analysis suggests that the DRD3 gene Ser9Gly variation confers susceptibility to schizophrenia. (PMID:12605094)
• An association analysis for dopamine D3 receptor polymorphism and p300 component in normal young women is negative. (PMID:12605102)
• Variations of the DRD3 gene are likely involved in the regulation of impulsivity and some psychopathological aspects of ADHD related to violent behavior. (PMID:12721816)
• extrastriatal D(2/3) density in drug-naive schizophrenic patients (PMID:12740603)
• Among type 1 alcoholics dopamine transporters are lower in nucleus accumbens and dopamine D(2), but not D(1) or D(3) receptors in nucleus accumbens and amygdala. Lower dopamine receptor density is specific for D(2) receptor and for type 1 alcoholism. (PMID:12781734)
• Chinese Han patients with schizophrenia assessed for abnormal involuntary movements and DRD3 polymorphism. (PMID:12960753)
• A shared variance of at least 17% (p=0.016) between DRD3 mRNA expression in peripheral blood lymphocytes and the personality trait of persistence is found. (PMID:15081259)
• dopaminergic neurons could regulate ERK activity more flexibly through alternative usage of either the D(2)R or D(3)R pathway depending on the cellular situation (PMID:15102843)
• The D3 receptor exhibits a tolerance property wherein the magnitude of the second agonist-induced response is reduced by 60%. The D3 receptor response terminates 15-fold more slowly upon agonist removal. (PMID:15121186)
• no associations between the dopamine receptor D3 BalI polymorphism and psychotic symptoms in Alzheimer’s disease (PMID:15342129)
• Phospholipase D activation is a novel finding for the D(3) receptor, and is the first example of an effector system where D(3) signals without G(i)/G(o) protein intermediates. (PMID:15500962)
• A single nucleotide polymorphism in the dopamine D3 receptor causes a shift from cAMP to a PGE2 signal transduction pathway. (PMID:15520413)
• the expression of DRD3 mRNA is reduced in schizophrenia and bipolar disorder. (PMID:15539862)
• The BDNF val66met genetic polymorphism may exert its effect on the clinically phenotypic variability after Tardive Dyskinesia has occurred. Further replication studies with larger sample size and stringent definition for TD is necessary. (PMID:15626824)
• DRD3 polymorphism may influence response to risperidone in negative symptoms and social functioning (PMID:15643094)
• D3R, filamin A, and beta-arrestin form a signaling complex that is destabilized by agonist- or expression-mediated increases in GRK2/3 activity (PMID:15687500)
• These results suggest that the DRD3 variant containing glycine is associated with more efficient striatal habit learning in healthy controls and patients with schizophrenia. (PMID:15998189)
• Interaction of the functional Val66Met polymorphism of the BDNF gene with DR# ser9gly polymorphism influencing age at onset in schizophrenia. (PMID:16056149)
• This study found diminished parietal and increased frontal P300 amplitudes in Gly9 homozygotes in comparison to Ser9 carriers. This finding suggests a possible role of the DRD3 receptor gene in the interindividual variation of P300 amplitudes. (PMID:16395310)
• DRD3 may contribute to the development of -compulsive personality disorder. (PMID:16583407)
• A glycine-9 variant DRD3 receptor may confer susceptibility to essential tremor. (PMID:16809426)
• Dopamine, D2/D3- and D4-specific agonists inhibited histamine- but not thrombin-induced VWF secretion; the dopamine effects are not mediated by Ca(2+)-dependent signalling or cAMP-mediated signaling (PMID:16839358)
• results did not support the hypothesis that Ser9Gly polymorphism of the DRD3 gene influences the response to typical antipsychotics in our sample of schizophrenics (PMID:17119697)
• No association was found between schizophrenia and the Ser9Gly polymorphism of the D3 dopamine receptor gene. (PMID:17171662)
• Presence of “non-negligible” specific [(123)I]epidepride binding to dopamine D(2)/D(3) receptors in the cerebellum. (PMID:17175177)
• Genetic variations within the DRD3 gene may not contribute significantly to interindividual differences in the therapeutic efficacy of risperidone in schizophrenia. (PMID:17429404)
• These results suggest a role for the dopamine D(3) receptor in the mediation of human prepulse inhibition (PMID:17579840)
• Monoclonal antibodies against all three D(2)-like receptors were used to localize receptors in Ntera-2 (NT-2) cells, the human neuronal precursor cell line and rat cerebral cortex and hippocampus. (PMID:17593530)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	drd3	ENSDARG00000032131
mus_musculus	Drd3	ENSMUSG00000022705
rattus_norvegicus	Drd3	ENSRNOG00000060806

Paralogs (25): DRD4 (ENSG00000069696), HRH3 (ENSG00000101180), HRH2 (ENSG00000113749), CHRM3 (ENSG00000133019), HRH4 (ENSG00000134489), TAAR5 (ENSG00000135569), GPR84 (ENSG00000139572), GPR161 (ENSG00000143147), TAAR2 (ENSG00000146378), TAAR6 (ENSG00000146383), TAAR8 (ENSG00000146385), TAAR1 (ENSG00000146399), HTR4 (ENSG00000164270), CHRM1 (ENSG00000168539), DRD5 (ENSG00000169676), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), CHRM4 (ENSG00000180720), CHRM2 (ENSG00000181072), DRD1 (ENSG00000184845), CHRM5 (ENSG00000184984), GPR21 (ENSG00000188394), HRH1 (ENSG00000196639), GPR52 (ENSG00000203737), TAAR9 (ENSG00000237110)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:94925) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 35 distinct phenotype terms.

Mouse phenotype (MP)	Records
hyperactivity	3
increased vertical activity	3
decreased anxiety-related response	2
increased exploration in new environment	2
abnormal physiological response to xenobiotic	2
abnormal body water content	1
small spleen	1
decreased locomotor activity	1
increased stereotypic behavior	1
head bobbing	1
decreased grooming behavior	1
abnormal cued conditioning behavior	1
decreased startle reflex	1
abnormal motor coordination/balance	1
abnormal reflex	1
abnormal locomotor activation	1
decreased alcohol consumption	1
abnormal food intake	1
increased susceptibility to weight gain	1
increased percent body fat/body weight	1
increased renin activity	1
decreased dopamine level	1
increased circulating leptin level	1
increased systemic arterial diastolic blood pressure	1
increased systemic arterial systolic blood pressure	1

+10 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pan troglodytes	P60026	100.0%	Diamond
Locusta migratoria	Q25321	99.4%	Diamond
Chlorocebus aethiops	P52702	99.1%	Diamond
Microtus montanus	Q9WTV8	99.0%	Diamond
Microtus ochrogaster	Q9WTV9	99.0%	Diamond
Xenopus laevis	Q9PU16	98.4%	Diamond
Ovis aries	P46628	97.8%	Diamond
Bos taurus	Q28031	97.8%	Diamond
Sus scrofa	P79399	97.3%	Diamond
Mustela putorius furo	Q6TLI9	97.3%	Diamond
Canis lupus familiaris	Q9GJU1	97.3%	Diamond
Meriones unguiculatus	O70432	94.0%	Diamond
Elephas maximus	O19014	91.3%	Diamond
Cavia porcellus	Q64077	90.5%	Diamond
Amblysomus hottentotus	O18935	90.2%	Diamond
Orycteropus afer	O19032	89.7%	Diamond
Caenorhabditis briggsae	Q61H86	89.1%	Diamond
Caenorhabditis elegans	Q6RYS9	89.1%	Diamond
Oryctolagus cuniculus	O77830	88.9%	Diamond
Macroscelides proboscideus	O19025	88.1%	Diamond
Erinaceus europaeus	O19012	86.4%	Diamond
Talpa europaea	O19091	84.6%	Diamond
Bombyx mori	Q17232	82.9%	Diamond
Heliothis virescens	Q25188	82.9%	Diamond
Meleagris gallopavo	O73810	79.6%	Diamond
Hemigrapsus sanguineus	Q25157	75.5%	Diamond
Takifugu rubripes	O42385	74.6%	Diamond
Didelphis virginiana	P35405	70.6%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
TIGIT	protein-coding	201633
ZNF80	protein-coding	7634
CCDC191	protein-coding	57577
QTRT2	protein-coding	79691

Protein

Protein identifiers

D(3) dopamine receptor — P35462 (reviewed: P35462)

Alternative names: Dopamine D3 receptor

All UniProt accessions (4): A0A8V8TLH3, E9PCM4, P35462, X5D2G4

UniProt curated annotations — full annotation on UniProt →

Function. Dopamine receptor that is primarily expressed in limbic areas of the brain and is involved in the modulation of cognitive, emotional, and endocrine functions. Plays a key role in regulating neuronal signaling pathways associated with motivation, reward, and behavior. Coupled to G(i)/G(o) proteins; activation leads to inhibition of adenylate cyclase and decreased intracellular cAMP levels. Involved in the control of locomotor activity and implicated in several neuropsychiatric disorders, including schizophrenia and substance use disorders. Promotes cell proliferation through MAP kinase signaling. Also involved in autophagy regulation: receptor activation stimulates AMPK, which phosphorylates RPTOR and enhances its interaction with MTOR, thereby inhibiting MTORC1 signaling and its downstream target RPS6KB1. This leads to activation of ULK1 and initiation of the autophagy cascade. Forms heterotetramers with DRD1 to potentiate beta-arrestin recruitment and mediate locomotor activity.

Subunit / interactions. Interacts with CLIC6. Interacts with GRK4. Interacts with PALM. Interacts with FLNA (via filamin repeat 21); increases PKA-mediated phosphorylation of FLNA. Interacts with DRD1.

Subcellular location. Cell membrane.

Tissue specificity. Brain.

Post-translational modifications. Phosphorylated by GRK4 (GRK4-alpha and GRK4-gamma). Palmitoylated.

Disease relevance. Tremor, hereditary essential 1 (ETM1) [MIM:190300] A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles may also be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant. Disease susceptibility is associated with variants affecting the gene represented in this entry. Glycine at position 9 results in gain of function and is associated with susceptibility to essential tremor. Schizophrenia (SCZD) [MIM:181500] A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder. Disease susceptibility may be associated with variants affecting the gene represented in this entry. Glycine at position 9 results in gain of function and may be a risk factor for schizophrenia.

Similarity. Belongs to the G protein-coupled receptor 1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P35462-1	1, D3	yes
P35462-3	3

RefSeq proteins (4): NP_000787, NP_001269492, NP_001277738, NP_387512 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR000929	Dopamine_rcpt	Family
IPR001620	Dopamine_D3_rcpt	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (44 total): helix 15, topological domain 8, transmembrane region 7, glycosylation site 4, binding site 3, disulfide bond 2, chain 1, splice variant 1, sequence variant 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

9 structures by resolution:

PDB	Title	Method	Resolution (Å)
7CMV	Dopamine Receptor D3R-Gi-PD128907 complex	ELECTRON MICROSCOPY	2.7
8IRT	Dopamine Receptor D3R-Gi-Rotigotine complex	ELECTRON MICROSCOPY	2.7
9T7P	Cryo-EM structure of ESG-2-36-bound D3 dopamine receptor with mini-Go	ELECTRON MICROSCOPY	2.85
3PBL	Structure of the human dopamine D3 receptor in complex with eticlopride	X-RAY DIFFRACTION	2.89
7CMU	Dopamine Receptor D3R-Gi-Pramipexole complex	ELECTRON MICROSCOPY	3
9F33	Cryo-EM structure of Dopamine 3 Receptor:Go complex bound to bitopic FOB02-04A - …	ELECTRON MICROSCOPY	3.05
9F34	Cryo-EM structure of Dopamine 3 receptor:Go complex bound to bitopic FOB02-04A - …	ELECTRON MICROSCOPY	3.09
9R42	Quinpirole-bound Dopamine D3 Receptor - Gi Protein Complex	ELECTRON MICROSCOPY	3.24
31BG	Cryo-EM structure of Dopamine 3 receptor:Go complex bound to bitopic AB13-46A	ELECTRON MICROSCOPY	3.47

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P35462-F1	75.70	0.47

Antibody-complex structures (SAbDab)

3 antibodies co-crystallized with this protein: 7CMU, 7CMV, 8IRT

Human Protein Atlas

Protein class: Transporters, G-protein coupled receptors, GPCRs excl olfactory receptors, Predicted membrane proteins, GPCRHMM predicted membrane proteins, Disease related genes, FDA approved drug targets, Small molecule drugs, Human disease related genes, Mental and behavioural disorders

Protein evidence: Evidence at protein level

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3)

Position	Role
110	eticlopride
345	eticlopride
349	eticlopride

Disulfide bonds (2)

Type	Positions
Disulfide bond	103–181, 355–358

Glycosylation sites (4)

Type	Positions
N-linked (glcnac…) asparagine	12, 19, 97, 173

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 8; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

8 pathways:

ID	Pathway	Evidence
R-HSA-390651	Dopamine receptors	curated
R-HSA-418594	G alpha (i) signalling events	curated
R-HSA-375280	Amine ligand-binding receptors	—
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	—
R-HSA-388396	GPCR downstream signalling	—
R-HSA-500792	GPCR ligand binding	—
R-HSA-162582	Signal Transduction	—
R-HSA-372790	Signaling by GPCR	—

MSigDB gene sets: 295 (showing top): GOBP_CIRCADIAN_RHYTHM, GOBP_POTASSIUM_ION_TRANSPORT, GOBP_G_PROTEIN_COUPLED_RECEPTOR_INTERNALIZATION, GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_MITOTIC_NUCLEAR_DIVISION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ETHANOL, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_ACID_SECRETION, GOBP_COGNITION, MODULE_274, GOBP_BEHAVIOR, GOBP_REGULATION_OF_BLOOD_PRESSURE, GOBP_NEGATIVE_REGULATION_OF_OLIGODENDROCYTE_DIFFERENTIATION, GOBP_CIRCULATORY_SYSTEM_PROCESS

GO Biological Process (40): G protein-coupled receptor internalization (GO:0002031), intracellular calcium ion homeostasis (GO:0006874), G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-activating dopamine receptor signaling pathway (GO:0007191), adenylate cyclase-inhibiting dopamine receptor signaling pathway (GO:0007195), learning or memory (GO:0007611), learning (GO:0007612), locomotory behavior (GO:0007626), visual learning (GO:0008542), response to xenobiotic stimulus (GO:0009410), regulation of dopamine secretion (GO:0014059), positive regulation of cytokinesis (GO:0032467), circadian regulation of gene expression (GO:0032922), response to histamine (GO:0034776), social behavior (GO:0035176), response to cocaine (GO:0042220), dopamine metabolic process (GO:0042417), regulation of potassium ion transport (GO:0043266), response to morphine (GO:0043278), negative regulation of blood pressure (GO:0045776), positive regulation of mitotic nuclear division (GO:0045840), acid secretion (GO:0046717), behavioral response to cocaine (GO:0048148), negative regulation of oligodendrocyte differentiation (GO:0048715), arachidonate secretion (GO:0050482), negative regulation of protein secretion (GO:0050709), musculoskeletal movement, spinal reflex action (GO:0050883), negative regulation of cytosolic calcium ion concentration (GO:0051481), regulation of dopamine uptake involved in synaptic transmission (GO:0051584), negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051898), negative regulation of synaptic transmission, glutamatergic (GO:0051967), prepulse inhibition (GO:0060134), phospholipase C-activating dopamine receptor signaling pathway (GO:0060158), positive regulation of dopamine receptor signaling pathway (GO:0060161), synaptic transmission, dopaminergic (GO:0001963), signal transduction (GO:0007165), adenylate cyclase-modulating G protein-coupled receptor signaling pathway (GO:0007188), negative regulation of G protein-coupled receptor signaling pathway (GO:0045744), regulation of amine transport (GO:0051952), regulation of secretion by cell (GO:1903530)

GO Molecular Function (4): dopamine neurotransmitter receptor activity, coupled via Gi/Go (GO:0001591), G protein-coupled receptor activity (GO:0004930), dopamine neurotransmitter receptor activity (GO:0004952), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), synapse (GO:0045202), membrane (GO:0016020)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Signaling by GPCR	2
Amine ligand-binding receptors	1
GPCR downstream signalling	1
Signal Transduction	1
GPCR ligand binding	1
Class A/1 (Rhodopsin-like receptors)	1

GO top-level categories

43 GO namespaces:

Category	Terms
G protein-coupled dopamine receptor signaling pathway	3
behavior	3
desensitization of G protein-coupled receptor signaling pathway	1
receptor internalization	1
intracellular monoatomic cation homeostasis	1
calcium ion homeostasis	1
G protein-coupled receptor activity	1
signal transduction	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
cognition	1
learning or memory	1
visual behavior	1
associative learning	1
response to chemical	1
dopamine secretion	1
regulation of catecholamine secretion	1
cytokinesis	1
regulation of cytokinesis	1
positive regulation of cell division	1
positive regulation of cell cycle process	1
circadian rhythm	1
regulation of gene expression	1
response to nitrogen compound	1
biological process involved in intraspecies interaction between organisms	1
response to alkaloid	1
response to oxygen-containing compound	1
catecholamine metabolic process	1
potassium ion transport	1
regulation of metal ion transport	1
response to isoquinoline alkaloid	1
regulation of blood pressure	1
dopamine neurotransmitter receptor activity	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
synaptic transmission, dopaminergic	1
dopamine binding	1
postsynaptic neurotransmitter receptor activity	1
binding	1
membrane	1
cell periphery	1
cell junction	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 14 of 47 annotations. The rest are phylogenetic / computational / electronic (IEA).

14 experimentally-supported GO terms:

GO term	NS	Evidence
G protein-coupled receptor internalization	BP	direct assay
G protein-coupled receptor signaling pathway	BP	direct assay
adenylate cyclase-activating dopamine receptor signaling pathway	BP	direct assay
adenylate cyclase-inhibiting dopamine receptor signaling pathway	BP	direct assay
arachidonate secretion	BP	direct assay
behavioral response to cocaine	BP	expression pattern
intracellular calcium ion homeostasis	BP	direct assay
negative regulation of protein secretion	BP	direct assay
positive regulation of cytokinesis	BP	mutant phenotype
prepulse inhibition	BP	mutant phenotype
response to cocaine	BP	expression pattern
response to histamine	BP	direct assay
plasma membrane	CC	direct assay
dopamine neurotransmitter receptor activity, coupled via Gi/Go	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,171 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DRD3	SLC6A4	P31645	779
DRD3	COMT	P21964	764
DRD3	SLC6A3	Q01959	749
DRD3	BDNF	P23560	741
DRD3	ANKK1	Q8NFD2	657
DRD3	MAOA	P21397	607
DRD3	DTNBP1	Q96EV8	592
DRD3	SLC18A2	Q05940	589
DRD3	GABRB2	P47870	585
DRD3	DISC1	Q9NRI5	578
DRD3	TOMT	Q8WZ04	576
DRD3	DAOA	P59103	558
DRD3	MAOB	P27338	548
DRD3	ZNF804A	Q7Z570	542
DRD3	TH	P07101	531

IntAct

Human interaction partners of DRD3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
RAMP1	physical association	0.400	1
RAMP2	physical association	0.400	1
RAMP3	physical association	0.400	1
ADORA2A	proximity	0.380	2
GPR143	proximity	0.380	2
DUSP14	association	0.350	1

BioGRID (40 interactions; top human partners by supporting records): PDCD6IP (Two-hybrid; 4 records), DRD1 (Affinity Capture-Western; 3 records), EPB41L1 (Reconstituted Complex; 3 records), USP48 (Affinity Capture-MS; 3 records), CLIC6 (Two-hybrid; 2 records), SLC9A3 (Affinity Capture-Western; 2 records), BRI3BP (Affinity Capture-MS), CSNK1D (Affinity Capture-MS), DSG4 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), FLNA (Two-hybrid), GIPC1 (Two-hybrid), GNAO1 (Affinity Capture-Western), GRB2 (Reconstituted Complex), HIST1H1B (Affinity Capture-MS)

SIGNOR signaling

showing 29 of 34 signaling interactions:

A	Effect	B	Mechanism
DRD3	“up-regulates activity”	GNAI1	binding
DRD3	“up-regulates activity”	GNAI3	binding
DRD3	“up-regulates activity”	GNAO1	binding
DRD3	“up-regulates activity”	GNAZ	binding
dopamine	“up-regulates activity”	DRD3	“chemical activation”
DRD3	“up-regulates activity”	GNB5	binding
amisulpride	“down-regulates activity”	DRD3	“chemical inhibition”
bromocriptine	“up-regulates activity”	DRD3	“chemical activation”
clozapine	“down-regulates activity”	DRD3	“chemical inhibition”
chlorpromazine	“down-regulates activity”	DRD3	“chemical inhibition”
haloperidol	“down-regulates activity”	DRD3	“chemical inhibition”
apomorphine	“up-regulates activity”	DRD3	“chemical activation”
pimozide	“down-regulates activity”	DRD3	“chemical inhibition”
domperidone	“down-regulates activity”	DRD3	“chemical inhibition”
sulpiride	“down-regulates activity”	DRD3	“chemical inhibition”
Isoetharine	“up-regulates activity”	DRD3	“chemical activation”
“1-phospho-alpha-D-glucuronic acid”	“up-regulates activity”	DRD3	“chemical activation”
“2-N,6-N-Bis(2,3-dihydroxy-N-benzoyl)-L-serine amide”	“up-regulates activity”	DRD3	“chemical activation”
“3-phenanthryl hydrogen sulfate”	“down-regulates activity”	DRD3	“chemical inhibition”
quinpirole	“up-regulates activity”	DRD3	“chemical activation”
sertindole	“down-regulates activity”	DRD3	“chemical inhibition”
zotepine	“down-regulates activity”	DRD3	“chemical inhibition”
ropinirole	“up-regulates activity”	DRD3	“chemical activation”
cis-(z)-Flupenthixol	“down-regulates activity”	DRD3	“chemical inhibition”
7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol	“up-regulates activity”	DRD3	“chemical activation”
LSM-20934	“down-regulates activity”	DRD3	“chemical inhibition”
2-[4-[3-[2-(trifluoromethyl)-9-thioxanthenylidene]propyl]-1-piperazinyl]ethanol	“down-regulates activity”	DRD3	“chemical inhibition”
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-13,14-diol	“up-regulates activity”	DRD3	“chemical activation”
(S)-(-)-sulpiride	“down-regulates activity”	DRD3	“chemical inhibition”

Protein complexes (CORUM) (7)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

7 complexes by size:

Complex	Subunits	Members
★ DRD3-NTSR1 complex	2	DRD3, NTSR1
★ DRD3-MTNR1A complex	2	DRD3, MTNR1A
★ DRD3-MTNR1B complex	2	DRD3, MTNR1B
★ DRD3-GPR143 complex	2	DRD3, GPR143
★ DRD1-DRD3 complex	2	DRD1, DRD3
★ DRD2(long)-DRD3 complex	2	DRD2, DRD3
★ D3 dopamine receptor	1	DRD3

Ligand–receptor pairs (CellPhoneDB) (4)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

4 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
DDC;SLC6A3	receptor	Signaling by Serotonin/Dopamine
DDC;SLC18A2	receptor	Signaling by Serotonin/Dopamine
DDC;SLC18A1	receptor	Signaling by Serotonin/Dopamine
DDC	receptor	Signaling by Serotonin/Dopamine

Disease & clinical

Genetic variants

Variant evidence for DRD3: 73 ClinVar records (0 pathogenic / likely pathogenic); 19 PharmGKB clinical annotations; 4 GWAS associations.

ClinVar

73 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	14
Benign	7

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 30 predictions of 806):

Position(s)	Effect	Δscore	Sites
3:114139498–114139499	donor_loss	1.0000	4
3:114139697–114139698	acceptor_loss	1.0000	6
3:114171721–114171722	donor_loss	1.0000	5
3:114172028–114172029	acceptor_loss	1.0000	6
3:114131117	donor_loss	0.9900	2
3:114139499	donor_loss	0.9900
3:114139699	acceptor_loss	0.9900
3:114172030	acceptor_gain	0.9900
3:114178656	donor_loss	0.9900
3:114131116–114131117	donor_loss	0.9800	3

AlphaMissense

1,008 missense substitutions predicted likely pathogenic (of 2,581 scored), across 236 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D75	8	0.998	1.000
D110	8	0.995	0.998
N47	8	0.992	0.999
N379	8	0.991	0.999
D127	8	0.987	0.995
S117	8	0.985	1.000
F197	8	0.985	0.999
F346	8	0.984	0.999
F338	8	0.983	0.999
S376	8	0.980	0.998
F345	8	0.974	0.999
F394	8	0.973	0.998
F390	8	0.968	0.999
S70	8	0.962	1.000
N375	8	0.962	0.999
F188	8	0.935	0.997
N65	8	0.932	0.999
S125	8	0.919	1.000
F386	8	0.914	0.993
F106	8	0.913	0.972

HPA cancer prognostics

RNA cancer specificity: Not detected

Disease associations

OMIM: gene MIM:126451 | disease phenotypes:

GenCC curated gene-disease

2 curated gene-disease records:

Disease	Classification	Inheritance	Records
schizophrenia	Limited	Autosomal dominant
tremor, hereditary essential, 1	Limited	Autosomal dominant

Mondo (2): schizophrenia (MONDO:0005090), tremor, hereditary essential, 1 (MONDO:0008590)

HPO phenotypes

12 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000738	Hallucinations
HP:0000746	Delusion
HP:0001260	Dysarthria
HP:0002174	Postural tremor
HP:0002345	Action tremor
HP:0002353	EEG abnormality
HP:0002378	Hand tremor
HP:0003676	Progressive
HP:0007086	Social and occupational deterioration
HP:0100753	Schizophrenia
HP:0410291	Negativism

GWAS associations

4 associations:

Study	Trait	p-value
GCST007576_302	Chronotype	2e-8
GCST006951_42	Feeling hurt	3e-8
GCST002111_8	Personality dimensions	6e-6
GCST002361_11	Smooth-surface caries	9e-6

EFO canonical traits (from GWAS)

3 canonical traits:

EFO ID	Trait name
EFO:0004365	personality trait
EFO:0009599	feeling emotionally hurt measurement
EFO:0008328	chronotype measurement

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
C536545	Tremor hereditary essential, 1 *(supp.)*

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL2095169 (SELECTIVITY GROUP), CHEMBL2096905 (PROTEIN FAMILY), CHEMBL2097165 (SELECTIVITY GROUP), CHEMBL2331075 (PROTEIN FAMILY), CHEMBL234 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the DRD3 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

11 curated-mechanism drugs:

Drug	Modality	Max phase
BLONANSERIN	Small molecule	4
CARIPRAZINE HYDROCHLORIDE	Small molecule	4
CHLORPROTHIXENE	Small molecule	4
LEVODOPA	Small molecule	4
SARIZOTAN HYDROCHLORIDE	Small molecule	3
TIAPRIDE	Small molecule	3
ABT-925	Small molecule	2
ADOPRAZINE	Small molecule	2
ETILEVODOPA	Small molecule	2
MESDOPETAM	Small molecule	2
TRAZPIROBEN	Small molecule	2

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes DRD3 — the drug acts on the assembly or class, not necessarily on this subunit alone.

21 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
AMISULPRIDE	Dopamine receptors; D2 & D3	2	4
AMOXAPINE	Dopamine receptor	5	4
APOMORPHINE HYDROCHLORIDE	D2-like dopamine receptor	3	4
BROMOCRIPTINE MESYLATE	D2-like dopamine receptor	3	4
CHLORPROMAZINE	D2-like dopamine receptor	3	4
DROPERIDOL	D2-like dopamine receptor	3	4
ERGOLOID MESYLATES	Dopamine receptor	5	4
HALOPERIDOL	D2-like dopamine receptor	3	4
HALOPERIDOL DECANOATE	D2-like dopamine receptor	3	4
LEVOMEPROMAZINE	D2-like dopamine receptor	3	4
LOXAPINE	D2-like dopamine receptor	3	4
OLANZAPINE	D2-like dopamine receptor	3	4
PERGOLIDE MESYLATE	Dopamine receptor	5	4
PIMOZIDE	Dopamine receptor	5	4
PRAMIPEXOLE DIHYDROCHLORIDE	D2-like dopamine receptor	3	4
PROMAZINE HYDROCHLORIDE	D2-like dopamine receptor	3	4
ROPINIROLE HYDROCHLORIDE	D2-like dopamine receptor	3	4
ROTIGOTINE	D2-like dopamine receptor	3	4
THIORIDAZINE	D2-like dopamine receptor	3	4
TRIFLUOPERAZINE HYDROCHLORIDE	D2-like dopamine receptor	3	4
PARDOPRUNOX	Dopamine receptors; D2 & D3	2	3

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 325,222 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

showing 60 of 448 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL2028019	CARIPRAZINE	4	1,672
CHEMBL2024517	CARIPRAZINE HYDROCHLORIDE	4	292
CHEMBL908	CHLORPROTHIXENE	4	9,392
CHEMBL1085	ACETOPHENAZINE	4	5,157
CHEMBL1738797	ALECTINIB	4	7,111
CHEMBL709	ALFUZOSIN	4	6,651
CHEMBL54349	ALPIDEM	4	1,703
CHEMBL1006	AMIFOSTINE	4	35,342
CHEMBL633	AMIODARONE	4	30,023
CHEMBL243712	AMISULPRIDE	4	10,675
CHEMBL629	AMITRIPTYLINE	4	53,007
CHEMBL1491	AMLODIPINE	4	39,830
CHEMBL489411	AMOROLFINE	4	7,839
CHEMBL1113	AMOXAPINE	4	20,303
CHEMBL1305	ANTAZOLINE	4	9,229
CHEMBL53	APOMORPHINE	4	26,040
CHEMBL1112	ARIPIPRAZOLE	4	24,497
CHEMBL1201192	ARMODAFINIL	4	14,629
CHEMBL3187365	ASENAPINE	4	146
CHEMBL296419	ASTEMIZOLE	4	21,684
CHEMBL641	ATOMOXETINE	4
CHEMBL1366	AURANOFIN	4
CHEMBL639	AZELASTINE	4
CHEMBL1200809	AZELASTINE HYDROCHLORIDE	4
CHEMBL701	BACLOFEN	4
CHEMBL46740	BAZEDOXIFENE	4
CHEMBL400599	BENFLUOREX	4
CHEMBL297302	BENPERIDOL	4
CHEMBL232201	BENZIODARONE	4
CHEMBL1201250	BENZQUINAMIDE	4
CHEMBL1201203	BENZTROPINE	4
CHEMBL12610	BENZYDAMINE	4
CHEMBL1008	BEPRIDIL	4
CHEMBL1293	BETA CAROTENE	4
CHEMBL290106	BITHIONOL	4
CHEMBL288441	BOSUTINIB	4
CHEMBL2105760	BREXPIPRAZOLE	4
CHEMBL493	BROMOCRIPTINE	4
CHEMBL1201245	BROMODIPHENHYDRAMINE	4
CHEMBL28218	BROMPERIDOL	4
CHEMBL49	BUSPIRONE	4
CHEMBL2110816	BUTRIPTYLINE	4
CHEMBL1201087	CABERGOLINE	4
CHEMBL1014	CANDESARTAN CILEXETIL	4
CHEMBL294199	CAPSAICIN	4
CHEMBL723	CARVEDILOL	4
CHEMBL1000	CETIRIZINE	4
CHEMBL790	CHLORHEXIDINE	4
CHEMBL71	CHLORPROMAZINE	4
CHEMBL1042	CHOLECALCIFEROL	4
CHEMBL1201284	CINACALCET	4
CHEMBL1200776	CINACALCET HYDROCHLORIDE	4
CHEMBL43064	CINNARIZINE	4
CHEMBL1729	CISAPRIDE	4
CHEMBL549	CITALOPRAM	4
CHEMBL1626	CLEMASTINE	4
CHEMBL2355051	CLOMIPHENE	4
CHEMBL415	CLOMIPRAMINE	4
CHEMBL104	CLOTRIMAZOLE	4
CHEMBL42	CLOZAPINE	4

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB clinical annotations

19 annotations by evidence level (1 strongest → 4):

Variant	Association	Level	Drugs	Phenotypes
rs167770	Efficacy	3	duloxetine	Anxiety Disorders
rs167771	Toxicity	3	risperidone	Bipolar Disorder;Schizophrenia
rs2654754	Toxicity	3	opioids	Opioid-Related Disorders
rs324023	Efficacy	3	duloxetine	Anxiety Disorders
rs324026	Efficacy	3	duloxetine	Anxiety Disorders
rs324029	Toxicity	3	opioids	Opioid-Related Disorders
rs6280	Efficacy	3	clozapine	Schizophrenia
rs6280	Toxicity	3	opioids	Opioid-Related Disorders
rs6280	Toxicity	3	levodopa	Gastrointestinal toxicity;Hallucinations;Parkinson Disease
rs6280	Efficacy	3	risperidone	Autism
rs6280	Efficacy	3	pramipexole	Parkinson Disease
rs6280	Efficacy	3	olanzapine	Schizophrenia
rs6280	Efficacy	3	paroxetine	Major Depressive Disorder
rs6280	Efficacy	3	methylphenidate	Autism Spectrum Disorder
rs6280	Metabolism/PK	3	quetiapine
rs6280	Toxicity	3	methamphetamine	HIV infectious disease
rs6280	Efficacy	3	risperidone	Schizophrenia
rs9288993	Toxicity	3	opioids	Opioid-Related Disorders
rs963468	Efficacy	3	duloxetine	Anxiety Disorders

PharmGKB variants

9 variants:

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6280	DRD3	3	5.00	11	pramipexole;opioids;paroxetine;risperidone;olanzapine;clozapine;methylphenidate;quetiapine;levodopa;methamphetamine
rs167770	DRD3	3	2.00	1	duloxetine
rs167771	DRD3	3	2.75	1	risperidone
rs324023	DRD3	3	2.00	1	duloxetine
rs324026	DRD3	3	2.00	1	duloxetine
rs963468	DRD3	3	2.00	1	duloxetine
rs2654754	DRD3	3	1.00	1	opioids
rs9288993	DRD3	3	2.00	1	opioids
rs324029	DRD3	3	2.00	1	opioids

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

27 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs6280	methylphenidate	Efficacy	Genotype TT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CC + CT.	PMID:23856854
rs6280	methylphenidate	Toxicity	Genotypes CT + TT is associated with increased intolerability of methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC.	PMID:23856854
rs6280	quetiapine	Metabolism/PK	Genotype TT is associated with increased clearance of quetiapine in healthy individuals as compared to genotypes CC + CT.	PMID:25025989
rs6280	levodopa	Toxicity	Genotype TT is associated with increased risk of gastrointestinal toxicity when treated with levodopa in people with Parkinson Disease as compared to genotypes CC + CT.	PMID:27779245
rs6280	levodopa	Toxicity	Genotypes CT + TT are associated with increased likelihood of Hallucinations due to levodopa in people with Parkinson Disease as compared to genotype CC.	PMID:30794329
rs6280	atorvastatin	Metabolism/PK	Genotype TT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotypes CC + CT.	PMID:26857559
rs2654754	opioids	Toxicity	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype AA.	PMID:33589790
rs9288993	opioids	Toxicity	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype AA.	PMID:33589790
rs324029	opioids	Toxicity	Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype GG.	PMID:33589790
rs6280	opioids	Toxicity	Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype TT.	PMID:33589790
rs324026	olanzapine	Efficacy	Allele C is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele T.	PMID:30886581
rs6280	antipsychotics	Efficacy	Genotypes CT + TT is associated with increased resistance to antipsychotics in people with Mood Disorders or Schizophrenia as compared to genotype CC.	PMID:37509727
rs324029	opioids	Toxicity	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype AA.	PMID:36744646
rs2654754	opioids	Toxicity	Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.	PMID:36744646
rs167770	sertraline	Efficacy	Genotype AG is associated with increased clinical benefit to sertraline in people with Obsessive-Compulsive Disorder as compared to genotype AA.	PMID:40513807
rs11721264	sertraline	Efficacy	Genotype AG is associated with increased clinical benefit to sertraline in people with Obsessive-Compulsive Disorder as compared to genotype GG.	PMID:40513807
rs6280	olanzapine	Efficacy	Genotype CC is associated with greater positive symptom improvement and positive symptom remission when treated with olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	PMID:18320559
rs6280	pramipexole	Efficacy	Allele T is associated with increased response to pramipexole.	PMID:19396436
rs6280	risperidone	Efficacy	Genotypes CC + CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT.	PMID:19997080
rs167771	risperidone	Toxicity	Allele G is associated with increased risk of extrapyramidal symptoms when treated with risperidone in people with Bipolar Disorder or Schizophrenia as compared to allele A.	PMID:19506579
rs6280	clozapine	Efficacy	Genotype TT is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.	PMID:21332319
rs6280	methamphetamine	Toxicity	Genotypes CC + CT are associated with increased risk of Cognitive disorder when exposed to methamphetamine in men with HIV Infections as compared to genotype TT.	PMID:21491142
rs963468	duloxetine	Efficacy	Genotype GG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + AG.	PMID:22249355
rs167770	duloxetine	Efficacy	Genotype AG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + GG.	PMID:22249355
rs324023	duloxetine	Efficacy	Genotype CT is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes CC + TT.	PMID:22249355
rs324026	duloxetine	Efficacy	Genotypes CC + CT are associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotype TT.	PMID:22249355
rs6280	paroxetine	Efficacy	Genotypes CC + CT are associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to genotype TT.	PMID:22926616

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Dopamine receptors

Most potent curated ligand interactions (63 total), top 25:

Ligand	Action	Affinity	Parameter
[3H]nemonapride	Antagonist	10.3	pKd
cariprazine	Partial agonist	10.05	pKi
[3H]spiperone	Antagonist	9.9	pKd
S33084	Antagonist	9.6	pKi
[3H]7-OH-DPAT	Agonist	9.6	pKd
lisuride	Partial agonist	9.6	pKi
perospirone	Antagonist	9.55	pKi
R-VK4-40	Antagonist	9.54	pKi
nafadotride	Antagonist	9.52	pKi
nemonapride	Antagonist	9.3	pKi
PG01037	Antagonist	9.2	pKi
spiperone	Antagonist	9.2	pKi
cabergoline	Partial agonist	9.1	pKi
[3H]PD128907	Agonist	9.0	pKd
terguride	Partial agonist	9.0	pKi
BP 897	Partial agonist	9.0	pKi
SB269652	Negative	9.0	pKi
flupentixol	Antagonist	8.96	pKi
roxindole	Partial agonist	8.9	pKi
sertindole	Antagonist	8.8	pKi
NGB 2904	Antagonist	8.8	pKi
eticlopride	Antagonist	8.8	pKi
(-)-N-porphynorapomorphine	Full agonist	8.7	pKi
pramipexole	Full agonist	8.7	pKi
haloperidol	Antagonist	8.6	pKi

Binding affinities (BindingDB)

4677 measured of 5410 human assays (6100 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
5-Bromo-N-(1-ethyl-pyrrolidin-2-ylmethyl)-2,3-dimethoxy-benzamide	KI	0.003 nM
[O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione	EC50	0.01 nM
CHEMBL5180504	KD	0.0149 nM
CHEMBL5198795	KD	0.0149 nM
CHEMBL1813595	KI	0.07 nM
7-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol	KI	0.1 nM
(Recemic)3-Propyl-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indol-9-ol	KI	0.1 nM
4-Cyano-1-methoxy-naphthalene-2-carboxylic acid (1-butyl-pyrrolidin-2-ylmethyl)-amide	KI	0.11 nM
6-(4-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)phenyl)-5,6-dihydroimidazo[2,1-b]thiazole	KI	0.12 nM
6-[Propyl-(2-thiophen-3-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol	KI	0.14 nM
CHEMBL1813594	KI	0.14 nM
3,3-diethyl-1-[(4R,7R)-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),2,9,12(16),13-pentaen-4-yl]urea	KI	0.15 nM
(S)-6-(propyl(2-(4-(quinolin-4-yl)piperazin-1-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol	KI	0.186 nM
4-[(R)-5-(4-Phenyl-3,6-dihydro-2H-pyridin-1-ylmethyl)-cyclohex-1-enyl]-phenol	KI	0.2 nM
2-(2,4-Dichloro-phenoxy)-N-[2-(2-dimethylamino-ethoxy)-4-methyl-quinolin-6-yl]-acetamide	IC50	0.2 nM
ethyl N-[4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]cyclohexyl]carbamate	KI	0.2 nM	US-9550741: Benzoisothiazole compounds and methods of treating schizophrenia
CHEMBL4083252	KI	0.22 nM
CHEMBL5192367	EC50	0.23 nM
2,4-dimethyl-5-(4-methyl-5-(3-(5-(4-(trifluoromethyl)phenyl)-2-azabicyclo[3.1.0]hexan-2-yl)propylthio)-4H-1,2,4-triazol-3-yl)thiazole	KI	0.25 nM
CHEMBL1813591	KI	0.26 nM
CHEMBL4538230	EC50	0.27 nM
biphenyl-4-carboxylic acid {4-[4-(2-chloro-phenyl)-piperazin-1-yl]-butyl}-amide	KI	0.28 nM
CHEMBL3798179	EC50	0.3 nM
2-(4-(4-(3-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione	EC50	0.3 nM
SB-649915	KI	0.316 nM
7-methyl-5,6,7,8,9,14-hexahydrodibenzo[d,g]azecin-3-ol	KI	0.355 nM
1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one	KI	0.38 nM
(3aS,6aS)-5-[3-[(5-cyclohexyl-4-methyl-1,2,4-triazol-3-yl)sulfanyl]propyl]-1-[4-(trifluoromethyl)phenyl]-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole	KI	0.398 nM	US-10273244: Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
CHEMBL112705	KI	0.398 nM
CHEMBL238520	KI	0.398 nM
CHEMBL2206265	EC50	0.44 nM
CHEMBL5276671	EC50	0.44 nM
PHNO,(+)	KI	0.45 nM
(2,4-Dimethyl-azetidin-1-yl)-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-methanone	KI	0.45 nM
4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenzo[d,g]azecin-3-ol	KI	0.46 nM
1-Chloro-2-hydroxy-7-methyl-5,6,7,8,9,14-hexahydrodibenzo[d,g]azecine	KI	0.46 nM
CHEMBL5425134	KI	0.48 nM
3,5-Dichloro-N-(1-ethyl-pyrrolidin-2-ylmethyl)-2-hydroxy-6-methoxy-benzamide(Raclopride)	KI	0.5 nM
6-Propylamino-5,6,7,8-tetrahydro-naphthalen-1-ol	KI	0.5 nM
4-Fluoro-N-{2-[4-(1,2,3,4-tetrahydro-naphthalen-1-yl)-piperazin-1-yl]-ethyl}-benzamide	KI	0.5 nM
N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1-ferra-1,1’-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2’,4,4’-tetraene-6-carboxamide	KI	0.5 nM
CHEMBL4099779	KI	0.5 nM
UNC10108016	EC50	0.5 nM	US-9156822: Functionally selective ligands of dopamine D2 receptors
N-[2-hydroxy-4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-1H-indole-2-carboxamide	KI	0.5 nM	US-8748608: 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use
N-[4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]cyclohexyl]-1H-pyrrole-2-carboxamide	KI	0.52 nM	US-9550741: Benzoisothiazole compounds and methods of treating schizophrenia
(11-Fluoro-2,3,3a,12b-tetrahydro-1-oxa-8-thia-dibenzo[e,h]azulen-2-ylmethyl)-dimethyl-amine	KI	0.56 nM
7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-11-ol	KI	0.56 nM
ethyl N-[4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]cyclohexyl]carbamate	KI	0.57 nM	US-9550741: Benzoisothiazole compounds and methods of treating schizophrenia
Thiophene-2-carboxylic acid (4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide	KI	0.6 nM
CHEMBL4071929	KI	0.631 nM

ChEMBL bioactivities

6100 potent at pChembl≥5 of 6100 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.92	Ki	0.012	nM	CHEMBL5841759
10.85	Ki	0.014	nM	CHEMBL5918571
10.85	Ki	0.014	nM	CHEMBL5802711
10.80	Ki	0.016	nM	CHEMBL5924177
10.70	Ki	0.02	nM	CHEMBL80919
10.70	Ki	0.02	nM	CHEMBL349426
10.66	Ki	0.022	nM	CHEMBL5833667
10.66	Ki	0.022	nM	CHEMBL5926122
10.60	Ki	0.025	nM	CHEMBL5870203
10.59	EC50	0.026	nM	CHEMBL4285942
10.59	Kd	0.0258	nM	PRAMIPEXOLE
10.59	Kd	0.0258	nM	CHEMBL5207281
10.59	Kd	0.0258	nM	CHEMBL5183205
10.59	Kd	0.0258	nM	CHEMBL5200771
10.59	Kd	0.0258	nM	CHEMBL5204599
10.59	Kd	0.0258	nM	CHEMBL5206565
10.59	Kd	0.0258	nM	CHEMBL5178472
10.59	Kd	0.0258	nM	CHEMBL5208845
10.59	Kd	0.0258	nM	CHEMBL5201074
10.59	Kd	0.0258	nM	CHEMBL5184911
10.59	Kd	0.0258	nM	CHEMBL5180504
10.59	Kd	0.0258	nM	CHEMBL5202592
10.59	Kd	0.0258	nM	CHEMBL5198795
10.59	Kd	0.0258	nM	CHEMBL5176229
10.59	Ki	0.026	nM	CHEMBL6037650
10.57	Ki	0.027	nM	CHEMBL1765633
10.54	Ki	0.029	nM	CHEMBL3905247
10.54	Ki	0.029	nM	CHEMBL5975724
10.52	Kd	0.03	nM	CHEMBL1774386
10.47	Ki	0.034	nM	CHEMBL5949574
10.46	Ki	0.035	nM	CHEMBL5880152
10.46	Ki	0.035	nM	CHEMBL5964833
10.41	Ki	0.039	nM	CHEMBL6060696
10.40	Ki	0.04	nM	BUTACLAMOL
10.40	Kd	0.04	nM	CHEMBL1774386
10.37	Ki	0.043	nM	CHEMBL3966842
10.37	Ki	0.043	nM	CHEMBL3918755
10.37	Ki	0.043	nM	CHEMBL5841988
10.36	Ki	0.044	nM	CHEMBL5875273
10.34	Ki	0.046	nM	CHEMBL3895540
10.33	Ki	0.047	nM	CHEMBL3920252
10.32	Ki	0.048	nM	CHEMBL5787369
10.32	Ki	0.048	nM	CHEMBL5951227
10.30	Ki	0.05	nM	CHEMBL5813094
10.29	Ki	0.051	nM	CHEMBL3932186
10.29	Ki	0.051	nM	CHEMBL5921899
10.28	Ki	0.052	nM	CHEMBL3902496
10.28	Ki	0.052	nM	CHEMBL5817877
10.26	Ki	0.055	nM	CHEMBL3896937
10.25	Ki	0.056	nM	CHEMBL3976282

PubChem BioAssay actives

3756 with measured affinity, of 6100 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]quinazolin-4-amine	65285: Binding affinity determined by measuring displacement of [3H]spiperone from cloned Human Dopamine receptor D3 in CHO-K1 cells	ki	<0.0001	uM
N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-2-carboxamide	1187750: Antagonist activity against human D3R expressed in CHO cells assessed as inhibition of dopamine-induced [35S]GTPgammaS binding by dopamine potency shift assay	ic50	<0.0001	uM
Pramipexole	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
N-[4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]cyclohexyl]-N-methylthiophene-2-sulfonamide	1332825: Displacement of [3H]methyl-spiperone from recombinant human D3 receptor expressed in CHO cell membranes after 60 mins by scintillation counting method	ki	<0.0001	uM
N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-1H-indole-2-carboxamide;hydrochloride	1413596: Agonist activity at human D3 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 4 hrs by luciferase reporter gene assay	ec50	<0.0001	uM
2-[4-[4-(2,3-difluorophenyl)piperazin-1-yl]butyl]isoindole-1,3-dione	1413596: Agonist activity at human D3 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 4 hrs by luciferase reporter gene assay	ec50	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-[2-methyl-3-(4-methylphenyl)propyl]urea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-[6-[[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]carbamoylamino]hexyl]urea;tetrakis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(2-amino-1,3-thiazol-5-yl)propyl]carbamimidoyl]-3-benzylurea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(2-amino-1,3-thiazol-5-yl)propyl]carbamimidoyl]-3-pentylurea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-[1-(3-fluorophenyl)ethyl]urea;dihydrochloride	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-(2-methyl-5-phenylpentyl)urea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[(1R)-1-phenylethyl]-3-[N’-[3-(1H-1,2,4-triazol-5-yl)propyl]carbamimidoyl]urea;dihydrochloride	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-hexylurea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(2-amino-1,3-thiazol-5-yl)propyl]carbamimidoyl]-3-[2-methyl-3-(4-methylphenyl)propyl]urea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-(2-cyclohexylpropyl)urea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-pentylurea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-benzylurea;bis(2,2,2-trifluoroacetic acid)	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
1-[N’-[3-(5-amino-1,3,4-thiadiazol-2-yl)propyl]carbamimidoyl]-3-[(1R)-1-phenylethyl]urea;dihydrochloride	1895204: Displacement of [3H]N-methylspiperone from human D3 receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay	kd	<0.0001	uM
N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-7-methoxy-1-benzofuran-2-carboxamide	258948: Displacement of [3H]spiroperidol from cloned human dopamine receptor D3 expressed in CHO cells	ki	0.0001	uM
3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea	1332825: Displacement of [3H]methyl-spiperone from recombinant human D3 receptor expressed in CHO cell membranes after 60 mins by scintillation counting method	ki	0.0001	uM
2-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-3,4-dihydropyrazino[1,2-a]indol-1-one	410333: Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry	ki	0.0001	uM
2-[4-[4-methyl-5-[3-[(2R,3S)-2-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propylsulfanyl]-1,2,4-triazol-3-yl]phenyl]-1,3-oxazole	1316390: Antagonist activity at human dopamine D3 receptor expressed in CHO cell membranes after 90 mins in presence of quinelorane by [35S]-GTPgammaS binding assay	ki	0.0001	uM
N-[4-(4-naphthalen-1-ylpiperazin-1-yl)butyl]-1H-indole-2-carboxamide	1236117: Displacement of [3H]-N-methylspiperone from human dopamine D3 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting	ki	0.0001	uM
N-[4-(4-naphthalen-1-ylpiperazin-1-yl)butyl]-1-benzothiophene-2-carboxamide	1236117: Displacement of [3H]-N-methylspiperone from human dopamine D3 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting	ki	0.0001	uM
N-[4-[4-(2-chloro-3-ethylphenyl)piperazin-1-yl]butyl]-1H-indole-2-carboxamide	1629096: Displacement of [3H]N-methylspiperone from human dopamine D3 receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis	ki	0.0001	uM
N-[4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]cyclohexyl]propanamide	1332825: Displacement of [3H]methyl-spiperone from recombinant human D3 receptor expressed in CHO cell membranes after 60 mins by scintillation counting method	ki	0.0001	uM
N-[[4-[[4-(6-chloro-1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]furan-2-carboxamide	1332825: Displacement of [3H]methyl-spiperone from recombinant human D3 receptor expressed in CHO cell membranes after 60 mins by scintillation counting method	ki	0.0001	uM
N-[4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]cyclohexyl]butanamide	1332825: Displacement of [3H]methyl-spiperone from recombinant human D3 receptor expressed in CHO cell membranes after 60 mins by scintillation counting method	ki	0.0001	uM
N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-methoxypropanamide	2026891: Displacement of [3H]N-methylspiperone from human D3 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method	ki	0.0001	uM
6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol	425420: Activity at human dopamine D3 receptor expressed in AtT cells assessed as stimulation of [35S]GTPgammaS binding	ec50	0.0001	uM
6-[2-(4-phenylpiperazin-1-yl)ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol	312287: Agonist activity at human cloned dopamine D3 receptor expressed in AtT-20 cells assessed as stimulation of [35S]GTP-gamma-S binding	ec50	0.0001	uM
6-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol	312287: Agonist activity at human cloned dopamine D3 receptor expressed in AtT-20 cells assessed as stimulation of [35S]GTP-gamma-S binding	ec50	0.0001	uM
6-N-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine	384700: Agonist activity at human dopamine D3 receptor expressed in mouse ATt-20 cells assessed as stimulation of [35S]GTPgammaS binding	ec50	0.0001	uM
(6S)-6-N-[2-[4-(4-phenylphenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine	446402: Agonist activity at human dopamine D3 receptor expressed in mouse AtT-20 cells assessed as stimulation of [35S]GTPgamma binding	ec50	0.0001	uM
6-N-[2-[4-(4-phenylphenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine	384700: Agonist activity at human dopamine D3 receptor expressed in mouse ATt-20 cells assessed as stimulation of [35S]GTPgammaS binding	ec50	0.0001	uM
3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea;hydrochloride	659797: Binding affinity to human dopamine D3 receptor	ki	0.0001	uM
3-[5-[4-(2,3-dichlorophenyl)piperazin-1-yl]pentoxy]isoquinoline	410333: Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry	ki	0.0001	uM
N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]isoquinoline-3-carboxamide	410333: Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry	ki	0.0001	uM
3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea	239943: Inhibition constant against [3H]-spiperone binding to human Dopamine receptor D3 expressed in CHO cells	ki	0.0001	uM
5-(3-fluoropropyl)-2,3-dimethoxy-N-[[(2S)-1-prop-2-enylpyrrolidin-2-yl]methyl]benzamide	2141240: Binding affinity to D3 receptor (unknown origin)	ki	0.0002	uM
4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-ol	65147: In vitro binding affinity at human Dopamine receptor D3 expressed in CHO K1 cells was measured by its ability to displace [3H]spiperone	ki	0.0002	uM
N-[4-[4-(2,4-dichlorophenyl)piperazin-1-yl]butyl]-1H-indole-2-carboxamide	410333: Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry	ki	0.0002	uM
5-bromo-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-1H-indole-2-carboxamide	277673: Displacement of [3H]spiperone from human dopamine D3 expressed in CHO cell membrane	ki	0.0002	uM
N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-4-phenylbenzamide	591963: Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells after 60 mins	ki	0.0002	uM
1-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-methylurea	2026891: Displacement of [3H]N-methylspiperone from human D3 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method	ki	0.0002	uM
(4aR,10bR)-4-(111C)propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-ol	539419: Binding affinity to human dopamine D3 receptor expressed in CHO cells	ki	0.0002	uM
N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]tricyclo[8.2.2.24,7]hexadeca-1(13),4,6,10(14),11,15-hexaene-5-carboxamide	266239: Displacement of [3H]spiperone from human D3 receptor expressed in CHO cells	ki	0.0002	uM
N-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1H-indole-2-carboxamide	1169861: Binding affinity to dopamine D3 receptor (unknown origin)	ki	0.0002	uM
4-[4-methyl-5-[3-[(2R,3S)-2-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propylsulfanyl]-1,2,4-triazol-3-yl]benzamide	1316392: Displacement of [3H]-spiperone from human dopamine D3 receptor expressed in CHO-K1 cell membranes after 90 mins by liquid scintillation counting	ki	0.0002	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
ropinirole	affects binding, increases activity	2
7-(N,N-dipropylamino)-5,6,7,8-tetrahydronaphtho(2,3-b)dihydro-2,3-furan	affects binding, decreases activity, increases activity, decreases reaction	2
nafadotride	affects binding, decreases activity, decreases reaction, increases activity	2
BP 897	affects binding, increases activity, decreases reaction	2
Cocaine	decreases expression, affects response to substance	2
Dopamine	increases activity, affects binding, increases reaction, decreases reaction	2
Spiperone	affects binding, decreases reaction	2
Risperidone	increases response to substance	2
propionaldehyde	decreases expression	1
1,2,3,4-tetrahydroisoquinoline	affects binding	1
fucoxanthin	increases activity	1
7-hydroxy-2-N,N-dipropylaminotetralin	affects binding, increases activity	1
benzo(f)quinoline	affects binding	1
iodosulpride	affects binding, decreases reaction	1
UH 232	affects binding, decreases activity	1
eticlopride	affects binding	1
quinelorane	affects binding, increases activity	1
5-methoxy-1-methyl-2-(n-propylamino)tetralin	affects binding, decreases activity	1
CGS 15855A	affects binding, increases activity	1
3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol	affects binding, increases activity	1
(5,6-dimethoxyindan-2-yl)dipropylamine	affects binding, decreases activity	1
CGP 52608	affects binding, increases reaction	1
A 86929	affects binding	1
3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole	affects binding, decreases activity	1
GR 218231	affects binding, decreases activity	1
7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine	affects binding	1
sarizotan	affects binding	1
((E)-N-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)butyl)-3-phenylacrylamide	affects binding, decreases activity	1
4-iodo-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)cinnamoylamide	affects binding	1
N-(4-(4-(3-aminocarbonyl-phenyl)-piperazin-1-yl)-butyl)-4-bromo-benzamide	affects binding, increases activity	1

ChEMBL screening assays

1359 unique, capped per target: 1088 binding, 262 functional, 6 admet, 3 unclassified

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL670661	Binding	Ratio of binding affinities towards human Dopamine receptor D2 and Dopamine receptor D3 receptors was determined	N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. — *J Med Chem*
CHEMBL827448	Functional	Dopamine receptor D2/D3 selectivity ratio from in vitro functional assays	Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. — *J Med Chem*
CHEMBL4048887	Unclassified	Selectivity ratio of Ki for human dopamine D3 receptor to Ki for human dopamine D4 receptor	1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D4 Receptor. — *J Med Chem*

Cellosaurus cell lines

3 cell lines: 2 spontaneously immortalized cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1B31	CHO-hD3	Spontaneously immortalized cell line	Female
CVCL_KW88	PathHunter CHO-K1 DRD3 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_LA20	PathHunter U2OS DRD3 beta-arrestin	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 301 trials:

NCT	Phase	Status	Title
NCT00000374	Phase 4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	Phase 4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	Phase 4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	Phase 4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	Phase 4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	Phase 4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	Phase 4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	Phase 4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	Phase 4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	Phase 4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	Phase 4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	Phase 4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	Phase 4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	Phase 4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	Phase 4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	Phase 4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	Phase 4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	Phase 4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	Phase 4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	Phase 4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	Phase 4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	Phase 4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	Phase 4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	Phase 4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	Phase 4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	Phase 4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	Phase 4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	Phase 4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	Phase 4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	Phase 4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	Phase 4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	Phase 4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	Phase 4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	Phase 4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	Phase 4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	Phase 4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	Phase 4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	Phase 4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	Phase 4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	Phase 4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
NCT00177580	Phase 4	COMPLETED	Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
NCT00182442	Phase 4	COMPLETED	Cognition, Functioning and Quality of Life
NCT00182494	Phase 4	UNKNOWN	Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00183625	Phase 4	COMPLETED	Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
NCT00186771	Phase 4	UNKNOWN	Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
NCT00190749	Phase 4	COMPLETED	Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
NCT00191555	Phase 4	COMPLETED	Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
NCT00194025	Phase 4	COMPLETED	Valproate in Late Life Schizophrenia
NCT00199940	Phase 4	COMPLETED	Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
NCT00202306	Phase 4	COMPLETED	Indicated Prevention of Psychotic Disorders With Low-dose Lithium
NCT00203788	Phase 4	COMPLETED	Improving Work Outcome in People With Recent-onset Schizophrenia
NCT00204061	Phase 4	COMPLETED	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
NCT00205660	Phase 4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00206102	Phase 4	COMPLETED	A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
NCT00208143	Phase 4	COMPLETED	Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
NCT00208169	Phase 4	COMPLETED	Abilify Therapy for Reducing Comorbid Substance Abuse
NCT00214578	Phase 4	COMPLETED	Seroquel on Glucose Metabolism
NCT00215579	Phase 4	COMPLETED	Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00216528	Phase 4	COMPLETED	A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
NCT00216632	Phase 4	COMPLETED	A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for DRD3 across ~30M SureChEMBL compounds — explore on Sugi Predict.